Kesatuan Eropah - Bulgaria - EMA (European Medicines Agency)

zoetis belgium sa - toceranib - Антинеопластични средства - Кучета - Лечение на нереакциращи, повтарящи се, тумори на костни мастно-клетъчни тумори на кучета тип ii (междинна степен) или -iii (висок клас) при кучета.

Bulgaria - Bulgaria - БАБХ (Българска агенция по безопасност на храните)

ВЕТПРОМ АД - Калциев глицерофосфат; borogluconate карбонат; натриев хлорид и магнезиев; глюкоза монохидрат - инжекционен разтвор - 7,629 g/100 ml; 5,32 g/100 ml; 3,14 g/ 100 ml; 16,5 g/100 ml - говеда, овце

Bulgaria - Bulgaria - БАБХ (Българска агенция по безопасност на храните)

ВЕТПРОМ АД - borogluconate на калций; магнезий глюконат; калций glicerophosphate; Глюкоза - инжекционен разтвор - 100 mg/ml; 60 mg/ml; 50 mg/ml; 50 mg/ml - агнета, говеда, кози, коне, котки, кучета, овце, прасета, свине, телета, ярета

Bulgaria - Bulgaria - БАБХ (Българска агенция по безопасност на храните)

richter pharma ag - Метамизол натрий, кофеин, Калциев глюконат, магнезиев глюконат, натриев дигидрофосфат дигидрат, acetylmethionine и/или глюкоза (като монохидрат) - инжекционен разтвор - 4.00 g/100 ml; 0,35 g/100 ml; 10.00 g/100 ml; 1.00 g/100 ml; 0, 402 g/100 ml; 4.00 g/100 ml; 18,182 g/100 ml - говеда, коне, свине, телета

Bulgaria - Bulgaria - БАБХ (Българска агенция по безопасност на храните)

Меди-Вет ООД - Монохидрат калциев глюконат; калциев ацетат; магнезиев хлорид hypophosphit - инжекционен разтвор - 465 mg/ml; 37 mg/ml; 30 mg/ml - кози

Bulgaria - Bulgaria - БАБХ (Българска агенция по безопасност на храните)

interchemie werken de adelaar eesti as - Калциев глюконат за инжекции, натриев хлорид, магнезиев хлорид Борна киселина - инфузионен разтвор - 380 mg, 60 mg, 50 mg/ml - говеда, овце, свине

Kesatuan Eropah - Bulgaria - EMA (European Medicines Agency)

mundipharma corporation (ireland) limited - Налоксона хидрохлорид дигидрат - Нарушения, свързани с опиоиди - Всички други терапевтични продукти - nyxoid е предназначен за незабавно прилагане като спешна терапия за известни или предполагаеми свръхдозата опиати, като проявява с дихателни или централната нервна система депресия в не медицински и здравни заведения. nyxoid is indicated in adults and adolescents aged 14 years and over. nyxoid is not a substitute for emergency medical care.

Bulgaria - Bulgaria - Изпълнителна агенция по лекарствата

gedeon richter plc. - Магнезий (различни соли в комбинация) - 158 mg/140 mg film - coated tablets

Kesatuan Eropah - Bulgaria - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - Артрит, ревматоиден - Имуносупресори - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Kesatuan Eropah - Bulgaria - EMA (European Medicines Agency)

novartis europharm limited - secukinumab - arthritis, psoriatic; psoriasis; spondylitis, ankylosing - Имуносупресори - plaque psoriasiscosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy. hidradenitis suppurativa (hs)cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hs therapy. Псориатичен arthritiscosentyx, самостоятелно или в комбинация с метотрексат (mtx), се предписва за лечение на активен псориатичен артрит при възрастни пациенти, когато в отговор на предишно заболяване дорабатывая анти-ревматични лекарства (dmards) терапия е неадекватна.. Аксиальный спондилит (axspa)анкилозиращ спондилит (като, радиографические аксиален спондилит)cosentyx е показан за лечение на активна анкилозирующего спондилита при възрастни, които недостатъчно са отговорили на стандартна терапия. non-radiographic axial spondyloarthritis (nr-axspa)cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (nsaids). juvenile idiopathic arthritis (jia)enthesitis-related arthritis (era)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. juvenile psoriatic arthritis (jpsa)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.